ACADIA’s $1B+ 2025 revenue outlook is driven by NUPLAZID and DAYBUE, with ACP-101 offering optional upside despite risks.

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $29.06, along ...

Acknowledging the limits of disease-modifying drugs like Leqembi and Kisunla, companies like Bristol Myers Squibb, Acadia, ...

In the assessment of 12-month price targets, analysts unveil insights for ACADIA Pharmaceuticals, presenting an average target of $33.37, a high estimate of $42.00, and a low estimate of $19.00.

It has been about a month since the last earnings report for Acadia Pharmaceuticals (ACAD). Shares have added about 26.1% in that time frame, outperforming the S&P 500.

Acadia Pharmaceuticals (NASDAQ: ACAD) is probably in better shape now than it's ever been. The biotech won approval last year for its lead product, Nuplazid, in treating Parkinson's disease psychosis.

ACADIA Pharmaceuticals (NASDAQ: ACAD) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table encapsulates ...

We have a conviction buy rating on Acadia Pharmaceuticals' common stock (price target of $47.57 based on sum-of-the parts DCF method). The company is also an attractive acquisition target.

Acadia Pharmaceuticals (ACAD 14.48%) is having a strong session Tuesday. Specifically, the drugmaker's shares were up by a healthy 6.7% on moderate volume at 10:02 a.m. ET.